Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA Dec 18 | 2020Novo Files Sema 2.4mg Obesity Indication with EMAPurchase Blast
$599
Posted in: Glucose Monitoring Dec 17 | 2020Nemaura Launches BEATdiabetes Program and proBEAT Non-invasive CGM in the USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 16 | 2020Novo to Initiate Oral Sema Alzheimer's Ph3 Program; Novo Ph3 High-dose Rybelsus Trial in 2021; Lilly to Initiate Tirzepatide HFpEF Trial; Highmark and BI Announce Jardiance OBC Results; Medtronic’s Sean Salmon Takes on CV Responsibilities; + Five Other News ItemsPurchase Blast
$599
Posted in: Other Dec 15 | 2020UPDATED - Entresto HFpEF Adcom: 12-1 Positive Vote, but End Result Remains ConfusingPurchase Blast
$599
Posted in: Glucose Monitoring, Other Dec 14 | 2020Lifescan Launches Online Store with Subscription-based Coaching Services; Welldoc Submits 510(k) with FDA to Expand Insulin Dosing Support; Biocon/Viatris (Mylan) Bs-aspart Receives Positive CHMP Opinion; Poxel Announces Ph2a data from PXL770 in NASHPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon Dec 11 | 2020Xeris Recieves Positive CHMP Opinion; Roche and Diabeloop Partner for AID DevelopmentPurchase Blast
$599
Posted in: Bolus Insulin, Other Dec 10 | 2020Novo Partners with Procyon Technologies for T1DM Stem-Cell Treatment; Bigfoot Expands Commercial Leadership Team; JDRF and Provention Bio Launch T1DM Screening Campaign; New Arecor Trial for Ultra-concentrated RAI; City of Hope Initiates Ph1 T1DM Vaccine TrialPurchase Blast
$599
Posted in: Glucose Monitoring Dec 10 | 2020Lifescan Redacts New CGM's Latest Trial RecordPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 09 | 2020Lilly Ph3 Tirzepatide SUPRASS-1 Data Lives up to Ph2b HypePurchase Blast
$599
Posted in: DPP-IVi, GLP-1RA Dec 07 | 2020Thoughts on Pediatric Exclusivity for Saxenda and JanuviaPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon Dec 07 | 2020Biocon/Mylan Bs-Aspart and Xeris Glucagon up for CHMP Opinions? CHMP Agenda December 7-10Purchase Blast
$599
Posted in: Basal Insulin Dec 07 | 2020Novo Retracts CONCLUDE (H2H Tresiba vs. Toujeo) Press ReleasePurchase Blast$599
Posted in: GLP-1RA Dec 04 | 2020Novo Files Sema 2.4mg Obesity Indication with FDAPurchase Blast
$599
Posted in: Glucose Monitoring Dec 03 | 2020Libre 2 Appears to Remain in US Soft Launch; When will Broad Launch Commence?Purchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
